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 Hereditary breast and ovarian cancer (HBOC) is caused by a mutation in the 
BRCA1 or BRCA2 genes.  Women with a BRCA1/2 mutation are at increased risks 
for breast and ovarian cancer and often develop cancer at an earlier age than the 
general population.  However, some women with a BRCA1/2 mutation do not 
develop breast or ovarian cancer under the age of 50 years.  There have been no 
specific studies on BRCA positive women with no cancer prior to age 50, therefore 
this study sought to investigate factors within these women with no cancer under 
age 50 with respect to reproductive risk factors, BMI, tumor pathology, screening 
history, risk-reducing surgeries, and family history.  241 women were diagnosed 
with cancer prior to age 50, 92 with cancer at age 50 or older, and 20 women were 
over age 50 with no cancer.  Data were stratified based on BRCA1 and BRCA2 
mutation status.  Within the cohorts we investigated differences between women 
who developed cancer prior to age 50 and those who developed cancer at age 50 
or older.  We also investigated the differences between women who developed 
cancer at age 50 or older and those who were age 50 or older with no cancer.  Of 
the 92 women with a BRCA1/2 mutation who developed cancer at age 50 or older, 
46 developed ovarian cancer first, 45 developed breast cancer, and one had breast 
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and ovarian cancer diagnosed synchronously.  BRCA2 carriers diagnosed age 50 
or older were more likely to have ER/PR negative breast tumors when compared to 
BRCA2 carriers who were diagnosed before age 50.  This is consistent with one 
other study that has been performed.  Ashkenazi Jewish women with a BRCA1 
mutation were more likely to be diagnosed age 50 or older than other ethnicities.  
Hispanic women with a BRCA2 mutation were more likely to be diagnosed prior to 
age 50 when compared to other ethnicities.  No differences in reproductive factors 
or BMI were observed.  Further characterization of BRCA positive women with no 
cancer prior to age 50 may aid in finding factors important in the development of 
breast or ovarian cancer. 
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BACKGROUND 
INTRODUCTION 
Hereditary breast and ovarian cancer (HBOC) is a hereditary cancer 
syndrome caused by mutations in the BRCA1 and BRCA2 genes.  HBOC has an 
autosomal dominant mode of inheritance and a high penetrance in mutation 
carriers.  Women with a BRCA1 or BRCA2 mutation are more likely to have an 
HBOC-related cancer, such as breast or ovarian, and may be diagnosed at a 
younger age than the general population.  Although individuals with this syndrome 
are at the greatest risk of developing breast or ovarian cancer, other cancers, such 
as prostate and pancreatic, are also associated with HBOC.  
BRCA1 was first cloned in 1994, followed by BRCA2 in 1995 (1).  BRCA2 
consists of 3,418 amino acids and, while little is known about its function, it is known 
to be involved in homologous recombination (1).  BRCA1 is 1,863 amino acids and 
plays a role in DNA repair, protein ubiquitinylation, chromatin remodeling, and cell-
cycle-checkpoint control (1).  Both of these genes play a role in preventing cancer 
from developing, specifically in the breasts and ovaries.  A mutation in one of these 
two genes leads to an increased risk of breast and ovarian cancer. 
The median age of ovarian cancer diagnosis in the general population is 63 
years of age (2).  Women with a BRCA1 or BRCA2 mutation often have a younger 
age at diagnosis than the general population.  The average age of ovarian cancer 
diagnosis in women with a BRCA1 mutation is 52.6 years and is 58.8 years in those 
with a BRCA2 mutation (3).  The lifetime chance for a woman in the general 
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population to develop ovarian cancer is 1.4% (2).  Individuals with a BRCA1 or 
BRCA2 mutation have a significantly increased chance to develop ovarian cancer 
with BRCA2 mutation carriers having a 27% risk for ovarian cancer by age 70 (4).  
BRCA1 carriers have an estimated ovarian cancer risk of 11-42% by age 60 (5).   
According to Surveillance, Epidemiology, and End Results (SEER) data, 
women in the general population have a 12.08% chance to develop breast cancer 
during their lifetime and the average age at diagnosis is 61 years of age (2).  
Estimates for female breast cancer in BRCA carriers are that 90% of BRCA1 carrier 
women will develop breast cancer and 41% of BRCA2 carrier women will develop 
breast cancer (3).  In addition to having higher lifetime risks of breast cancer, 
women with a BRCA1 or BRCA2 mutation are often diagnosed at significantly 
younger ages than the general population.   
A meta-analysis of 22 studies unselected for family history showed that by 
age 50, it was estimated that approximately 40% of BRCA1 carriers would develop 
breast cancer and that approximately 12% would develop ovarian cancer (6).  In 
BRCA2 carriers it was estimated that approximately 15% would develop breast 
cancer by age 50 and approximately 3% would develop ovarian cancer by age 50.  
A study of 676 Ashkenazi Jewish families and 1,272 families of other ethnicities in 
the US showed that the cumulative risk to age 50 for BRCA1 carriers was 28% (CI 
24-34) for breast cancer and 13% (CI 9.7-17) for ovarian cancer (6).  The 
cumulative risks for BRCA2 carriers were 23% (CI 19-29) for breast cancer and 4% 
(CI 2.2-6.2) for ovarian cancer by age 50 (6).  These two studies differ in their 
breast cancer risk estimates among BRCA1 and BRCA2 carriers (40% vs. 28% for 
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BRCA1 and 15% vs. 23% for BRCA2), however the ovarian cancer risk estimates 
are quite similar (12% vs. 13% for BRCA1 and 3% vs. 4% for BRCA2). 
There have been many studies investigating breast and ovarian cancer risk 
factors in women with a BRCA1 or BRCA2 mutation, however many of these 
studies have focused on women with early-onset breast or ovarian cancer.  There is 
very limited information about these factors in women with a later-onset of breast or 
ovarian cancer or in older women who have not developed breast or ovarian 
cancer.  There may be factors that influence the chance that a woman with a 
BRCA1 or BRCA2 mutation does not develop breast cancer at a younger age.  To 
our knowledge, there have been no studies performed to identify factors in BRCA 
positive women with later-onset (≥50 years old) breast or ovarian cancer and 
compare the factors to women who developed breast or ovarian cancer at an earlier 
age (<50 years old).  
 
REPRODUCTIVE RISK FACTORS 
In addition to BRCA mutation status, there are other risk factors known to 
influence whether or not a woman will develop breast or ovarian cancer.  Certain 
reproductive factors can increase risk or play a protective role in whether or not a 
woman develops breast or ovarian cancer.  These factors include parity, age at first 
full-term pregnancy, age of menarche, age at menopause, breastfeeding, oral 
contraceptive use, and hormone replacement therapy use. 
Later age of menarche has been associated with a decreased risk of breast 
cancer in the general population.  Early menarche may induce an early proliferation 
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of mammary gland cells through early exposure to high hormonal levels causing an 
increased risk of breast cancer (7), therefore early menarche (prior to age 12) is 
associated with a higher lifetime risk of breast cancer in the general population (8).  
One study found a later age of menarche in BRCA1 mutation carriers was 
associated with a decreased breast cancer risk, however no protective effect was 
observed in BRCA2 mutation carriers (9).  Another study showed no association 
with age at menarche and breast cancer risk in BRCA1 or BRCA2 mutation 
carriers(10). 
Ovarian cancer risk is decreased among women with a later age of 
menarche.  Among BRCA1 and BRCA2 carriers, there has not been any significant 
evidence that age at menarche is positively or negatively associated with ovarian 
cancer risk (11).  
Women in the general population have an increased risk of breast cancer if 
they undergo menopause at a later age.  This is likely due to the increased duration 
and amount of estrogen and progesterone (7).  A study of BRCA1 and BRCA2 
mutation carriers found no overall association with menopause and breast cancer 
risk (10).  Early menopause has also been found to be protective against ovarian 
cancer.  One particular study found early menopause to confer an odds ratio of 0.6 
when women who underwent menopause prior to age 45 were compared to those 
who underwent menopause after age 45 (12).  There have been no studies that 
explore the relationship between age at menopause and ovarian cancer in women 
with a BRCA1 or BRCA2 mutation. 
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Early age at first full-term pregnancy is associated with a decreased risk for 
breast cancer in the general population.  Women under age 18 at their first full-term 
pregnancy have only 40% of the breast cancer rates of women with no pregnancies 
(13).  In addition, late pregnancies may increase breast cancer risk for women in the 
general population.  Women with their first full-term pregnancy occurring after age 
35 showed a 20% higher risk of developing breast cancer than those who were 
nulliparous (13). The role of pregnancy in the etiology of BRCA-breast cancer is not 
clear.   In women with a BRCA1 or BRCA2 mutation, early full-term birth was not 
found to be protective against breast cancer (14), suggesting that the factors 
playing a role in the general population may not be applicable to women who are 
genetically predisposed to developing breast cancer.  In BRCA2 carriers, first 
childbirth at later ages has been associated with an increased risk for breast cancer 
when compared to those with their first childbirth prior to age 20 (11).  In BRCA1 
mutation carriers, first full-term pregnancy after age 30 has been associated with a 
reduction of breast cancer risk compared to those whose first full-term pregnancy 
occurred before age 20 (15).  As this is in contradiction to findings in the general 
population, this further suggests that factors playing a role in the general population 
may not be applicable to BRCA carriers.  In the general population, later age at first 
birth is associated with a reduced risk of ovarian cancer.  This same association has 
been seen in both BRCA1 and BRCA2 carriers (16). 
An increasing number of full-term pregnancies has been associated with a 
decreased risk for breast cancer in the general population.  Some studies suggest 
that this may be due to decreased levels of estrogen and progesterone, increased 
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levels of sex hormone-binding globulin, and pregnancy-induced differentiation of 
breast tissue (12).  A study performed in a population of BRCA1 and BRCA2 
mutation carriers found a decreased risk of breast cancer as the number of full-term 
pregnancies increased (9), however the results were not statistically significant.  
Another study found no statistically significant difference in the risk of breast cancer 
between parous and nulliparous women (15).  For carriers and noncarriers of a 
BRCA1 or BRCA2 mutation, women who have had four or more full-term 
pregnancies had a near fifty percent reduction of breast cancer risk when compared 
to nulliparous women (9).  This protective effect was mainly limited to women who 
had their first full-term pregnancy prior to age 25.  Among women over age 40 with 
a BRCA mutation who have had a full-term pregnancy, an increasing number of full-
term pregnancies was associated with a 14% decrease in the breast cancer risk for 
each pregnancy (15). 
Women in the general population have a decreased ovarian cancer risk as 
parity increases.  One study found that parity was associated with a decreased risk 
of ovarian cancer in BRCA1 carriers and an increased risk of ovarian cancer in 
BRCA2 carriers (17).  Another study identified the same protective effects of parity 
in BRCA1 carriers but did not identify any significant association between parity and 
ovarian cancer risks in BRCA2 carriers (16).  
A longer duration of breastfeeding has been found to decrease the breast 
cancer risk in the general population.  Several theories have been proposed to 
explain this observation, including postponed resumption of ovulatory menstrual 
cycles, breast tissue differentiation, decreased estrogen levels, and excretion of 
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carcinogens from the breast ductal tissue (9).  A longer duration of breast-feeding 
has not been found to have a decreased risk of breast cancer in BRCA2 mutation 
carriers (9, 15, 18).  While some studies have shown breast-feeding to have no 
effect in BRCA1 mutation carriers (9, 15), one study found that women with a 
BRCA1 mutation who breast-fed for more than one year were 45% less likely to 
have breast cancer than those who had never breast fed (13).   
Breastfeeding among the general population confers a decreased risk of 
developing ovarian cancer.  In one study of women with a BRCA1 mutation, breast-
feeding was shown to be protective against ovarian cancer (17), however other 
studies have found no association among BRCA1 or BRCA2 carriers’ ovarian 
cancer risk and breastfeeding (11). 
Studies on the use of oral contraceptives and its influence on breast cancer 
have not been conclusive.  Some studies show that oral contraceptive use is not 
associated with breast cancer risk in the general population or in BRCA1 or BRCA2 
mutation carriers (9).  In a meta-analysis, women currently using combined oral 
contraceptives or women who had used them in the past 10 years were found to 
have a slightly increased risk of breast cancer (19).  They found no evidence of an 
increased risk of breast cancer diagnosed 10 or more years after discontinuing use.  
Women who had ever used oral contraceptives had a relative risk of 1.07 of 
developing breast cancer when compared to women who had never used oral 
contraceptives (19).  One study showed a decreased risk of breast cancer among 
BRCA1 mutation carriers, although the results were not statistically significant (9).  
Another study found that BRCA1 mutation carriers who used oral contraceptives for 
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5 years or longer had an increased risk for breast cancer when compared to BRCA1 
carriers who did not use oral contraceptives (odds ratio 1.33) (20).  However, oral 
contraceptive use after age 30 was not likely to increase the risk of breast cancer 
among BRCA1 mutation carriers (20).  This study did not find an association among 
BRCA2 carriers and oral contraceptive use, although the sample size for this group 
was small (20).  Given that numerous studies have been done on this topic and 
there are contradictions between them, there is currently no real consensus on the 
effect of oral contraceptives on breast cancer risk.  However, oral contraceptive use 
has consistently been found to reduce the risk of ovarian cancer in the general 
population as well as in women with a BRCA1 or BRCA2 mutation (17). 
Hormone replacement therapy (HRT) has been found to increase the risk of 
breast cancer in the general population and the risk of breast cancer increases with 
increasing duration of HRT (21).  A study of BRCA1 mutation carriers did not find 
that HRT was associated with an increased risk of breast cancer (22).  This study 
also did not find an association between the duration of HRT use and the risk of 
breast cancer among women with a BRCA1 mutation.  An increased risk of ovarian 
cancer has been associated with HRT use in the general population, however there 
have been some conflicting studies and the ovarian cancer and HRT relationship is 
not quite clear in the literature (23-25).  There was no association between HRT and 
ovarian cancer risk seen in a study looking at BRCA positive women (26).     
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BODY MASS INDEX (BMI) 
Body mass index (BMI) is calculated from a person’s height and weight.  A 
higher BMI has been associated with a decreased risk of breast cancer prior to 
menopause and is minimally associated with an increased risk for breast cancer 
after menopause (27).  The increased risk for breast cancer in heavier 
postmenopausal women may be attributed to higher levels of estrogen in the 
woman since the primary source of estrogen after menopause is the conversion of 
androstenedione to estrone in adipose tissue (28).  When comparing 
postmenopausal women who have the highest BMI to postmenopausal women who 
have the lowest BMI, studies report a relative risk of breast cancer of 1.5-2.0 (28).  
In women with a BRCA mutation, increases or decreases in body weight during 
early adult life may be more important in determining the risk for breast cancer than 
current weight or BMI (29). 
The association of ovarian cancer and BMI has not been consistent.  Some 
studies show that ovarian cancer risk increases in the general population as BMI 
increases (30, 31).  In a meta-analysis of 28 studies, the risk of epithelial ovarian 
cancer among obese women was estimated to be 30% higher than women with a 
normal BMI and women considered overweight had a 16% increased risk of ovarian 
cancer when compared to women with a normal BMI (30).  The association 
between ovarian cancer and BMI may depend on a woman’s menopausal status.  
BMI has been associated with an approximately 2-fold increased ovarian cancer 
risk among premenopausal women (age <50 years), however among 
postmenopausal women there was no significant association between BMI and 
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ovarian cancer (32).  There have been no studies, to our knowledge, looking at the 
association between BMI and ovarian cancer in women with a BRCA1/2 mutation.  
However, some studies have shown that in women who have a family history of 
ovarian cancer, there is no association between BMI and ovarian cancer (31).   
 
SCREENING MODALITIES AND FREQUENCIES 
There have been specific recommendations made for women who have a 
BRCA1 or BRCA2 mutation in order to screen for breast and ovarian cancer.  These 
recommendations are in place to help detect these types of cancer at a stage that 
is, ideally, earlier and more treatable.  The National Comprehensive Cancer 
Network (NCCN) has developed a set of practice guidelines for cancer screening in 
women with a BRCA1 or BRCA2 mutation.  The 2009 guidelines include breast self-
examination monthly beginning at age 18 as well as clinical breast exams 
semiannually beginning at age 25.  Annual mammograms and breast MRI should 
begin at age 25.  To screen for ovarian cancer, the NCCN guidelines recommend 
concurrent transvaginal ultrasound and CA-125 blood test every 6 months 
beginning at age 35 or 5-10 years prior to the earliest age of ovarian cancer onset in 
the family.  Ovarian cancer screening has not been shown to be effective, therefore 
it is recommended that women with an increased risk to develop ovarian cancer 
undergo risk-reducing bilateral salpingo-oophorectomy (33). 
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CHEMOPREVENTION 
Chemopreventive agents, such as tamoxifen, may be offered to women at an 
increased risk of breast cancer based on personal history, family history, or BRCA 
mutation status.  Tamoxifen targets the estrogen receptor (ER) in breast cells, 
therefore tamoxifen may not have as great an effect on ER negative breast cancers.  
Given that many BRCA1-related breast cancers tend to be ER negative, tamoxifen 
may not significantly reduce breast cancer risk among BRCA1 mutation carriers.  
Tamoxifen use does not have an effect on ovarian cancer risk (34).   
Women in the general population receive protection against breast cancer 
when taking tamoxifen.  Women who took tamoxifen for seven years had a rate of 
breast cancer of 24.8 per 1000 as compared to 42.5 per 1000 women in the 
placebo group (35). 
While no large studies to date have assessed the effect of tamoxifen on 
BRCA1 and BRCA2 carriers that do not have a history of breast cancer, studies 
have shown a decreased risk of contralateral breast cancer in BRCA1 and BRCA2 
mutation carriers (36).  The risk of contralateral breast cancer was decreased by 
greater than 50% in BRCA1/2 mutation carriers when tamoxifen was used as 
treatment for their initial breast cancer diagnosis (36).  Given this data, it is 
reasonable to assume that tamoxifen use in women with a BRCA1 or BRCA2 
mutation who have never had a breast cancer diagnosis would experience a 
decreased risk of developing breast cancer, however no large studies have been 
reported.  One study observed women with no previous breast cancer diagnosis 
and found that of the 8 women with a BRCA1 mutation who developed breast 
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cancer, 5 were taking Tamoxifen and 3 were in the placebo group (risk ratio 1.67) 
(34).  In this same study, of 11 women with BRCA2 mutations who developed 
breast cancer, 3 were taking tamoxifen and 8 were in the placebo group (risk ratio 
0.38) (34).  Given the small sample size, general inferences cannot be made, 
however it appears that tamoxifen use may be effective in BRCA2 mutation carriers, 
but not in those with a BRCA1 mutation. 
 
RISK-REDUCING SURGERIES 
Bilateral mastectomy and bilateral salpingo-oophorectomy (BSO) are often 
recommended to women with a BRCA1 or BRCA2 mutation to decrease the chance 
of developing breast and/or ovarian cancer.  Mastectomy reduces the risk of breast 
cancer while BSO reduces the risk of both breast and ovarian cancer (37-42).  The 
hypothesis for why BSO affects breast cancer risk is that estrogen deprivation 
reduces the risk of breast cancer (37).   
Prophylactic BSO decreases the chance for ovarian cancer to develop in 
women with a BRCA1 or BRCA2 mutation.  Prospective studies identified a reduced 
risk of ovarian cancer in BRCA1 carriers (39).  While protection was suggested for 
BRCA2-associated ovarian cancer in this study, it did not reach statistical 
significance, likely due to the small number of BRCA2 carrier (39).  A meta-analysis 
of 10 studies found an 80% reduction of ovarian cancer after BSO (42).  Another 
study that was performed showed a 96% reduction of ovarian cancer risk after BSO 
(43). 
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BSO has been associated with a 57% reduction in breast cancer risk in 
BRCA1 carriers and a 46% risk reduction in BRCA2 carriers (37).  Another study 
showed a hazard ratio of 0.53 for breast cancer risk in BRCA1 mutation carriers 
who had undergone prophylactic BSO when compared to BRCA1 carriers who had 
not undergone the surgery (38).  While oophorectomy at a premenopausal age 
decreases the risk for breast cancer throughout a woman’s lifetime, the effect 
appears greater for breast cancers diagnosed before age 50 (37-39).  A prospective 
study found that prophylactic BSO was associated with a significant decreased risk 
of breast cancer in BRCA2 mutation carriers (39).  Other studies have shown an 
approximately 50% risk reduction of developing breast cancer following a 
premenopausal BSO (42, 43). 
Bilateral mastectomy reduces a woman’s risk of breast cancer by 
approximately 90% if she carries a BRCA1 or BRCA2 mutation (41).  In a group of 
76 women with a BRCA1 or BRCA2 mutation who chose to undergo prophylactic 
mastectomy, none of them developed breast cancer whereas in a group of 63 
women with a BRCA1 or BRCA2 mutation who did not undergo the surgery, 8 
women developed breast cancer (40).  Another study showed that 1.9% of 
BRCA1/2 carriers were diagnosed with breast cancer after prophylactic mastectomy 
whereas 48.7% of controls were diagnosed with breast cancer (41).   
Women may choose to undergo prophylactic mastectomy and/or BSO in 
order to greatly reduce their chances of developing breast and/or ovarian cancer, 
however there are many psychosocial concerns that may also affect whether or not 
a woman chooses to have the surgery done.  In addition, even if a woman chooses 
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to undergo these procedures, there is still a risk for her to develop breast and/or 
ovarian cancer (primary peritoneal cancer) as the procedures do not confer a 100% 
reduction of cancer risk. 
 
HORMONE RECEPTOR STATUS 
Hormone receptor status has been found to vary among breast cancers and 
can also have prognostic factors for the cancer.  Estrogen and progesterone are 
important in the development and progression of breast cancer.  Estrogen receptor 
(ER) and progesterone receptor (PR) status have been found to be the most 
important predictors of endocrine therapy response (44).  Approximately 65% of 
female breast cancers are ER positive and 50% are PR positive (45).  ER and PR 
status tend to be positive more often in patients whose tumor developed at an older 
age (45).  Tumors that are ER and PR positive tend to have a better response to 
endocrine therapies and have a better prognosis when compared to women with ER 
and PR negative tumors (46).   
Studies have found that women with a BRCA1 mutation are more likely to 
have ER/PR negative breast cancers than women with a BRCA2 mutation or 
women with no BRCA mutation (47-49).  A study by Atchley et al (47) found that 
women with triple-negative breast cancer who were BRCA2 mutation carriers were 
diagnosed at a later age than BRCA1 mutation carriers and noncarriers. 
Her-2/neu status is another pathological characteristic found in breast 
cancer.  Her-2/neu is a proto-oncogene that has been identified in up to 34% of 
breast cancers (50).  The amplification and protein overexpression of Her-2/neu is 
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associated with an adverse outcome in breast cancer (50).  There have been 
inconsistent findings when identifying the relationship between Her-2/neu status and 
BRCA1 and BRCA2 mutations.  Some studies have found that Her-2/neu status 
among BRCA1 mutation carriers does not differ when compared to noncarriers (47), 
however other studies have reported that BRCA1 status is associated with Her-
2/neu-negative breast cancers (51).   
Many studies have looked at early-onset breast cancer and the association 
with ER, PR, and Her-2/neu status.  We could not find any studies that look at this 
association between women with a BRCA1 or BRCA2 mutation who were 
diagnosed with breast cancer at a later age.  It is largely unknown whether or not 
there is a difference in ER, PR, and Her-2/neu status when comparing women with 
early- vs. late-onset breast cancer. 
 
ETHNICITY 
The incidence of breast cancer in the general population varies by 
race/ethnicity.  White women have the highest breast cancer incidence (141.1 in 
100,000 females) followed by African Americans (119.4), Asian Americans/Pacific 
Islanders (96.6) and Hispanics/Latinas (89.9) (52).  American Indians/Alaska 
Natives have the lowest incidence of breast cancer (54.8) (52).  White women in the 
United States are at a higher risk for developing ovarian cancer (13.1 in 100,000) 
than American Indians (10.2), Hispanics (9.4), African Americans (9.0) and 
Asian/Pacific Islanders (8.0) (53).   
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Given that white women are at the highest risk to develop breast and ovarian 
cancer, it is reasonable to presume that a white woman with a BRCA1 or BRCA2 
mutation may be at higher risk to develop breast and/or ovarian cancer than a 
Hispanic/Latina with a BRCA1/2 mutation.  In individuals with a breast cancer 
diagnosis, BRCA1 and BRCA2 mutation rates across ethnic groups are fairly similar 
with a rate of 1-4% for each gene (54).  Therefore, the differences in prevalence of 
breast and ovarian cancer among different ethnic/racial populations cannot be 
explained exclusively by the rate of mutations in the BRCA1 and BRCA2 genes in 
those populations.  There are likely other genetic factors within racial groups that 
influence a woman’s risk of developing breast or ovarian cancer.  
 
FAMILY HISTORY 
A family history of breast or ovarian cancer increases the risk for a woman to 
develop these types of cancers.  One study showed that having two or more first-
degree female relatives with breast cancer is associated with an increased risk to 
develop ovarian cancer (OR 9.5; CI 1.0-87.0), however there were very few cases 
and this may be due to chance (55).  In a meta-analysis of women with a family 
history of ovarian cancer, the relative risk to first-degree relatives was 3.1 (56).  
Sisters of a woman with ovarian cancer had a higher relative risk (3.8) of ovarian 
cancers than mothers of cases (1.1) (56).  Daughters of cases had the highest 
relative risk of ovarian cancer (6.0) (56). 
A family history of breast cancer confers a greater risk of breast cancer in an 
individual.  In a meta-analysis of 74 studies of breast cancer risk and family history, 
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it was found that a woman with any first-degree relative affected with breast cancer 
has a relative risk of 2.1 when compared to women with no family history of breast 
cancer (57).  A woman with a mother diagnosed with breast cancer has a 2.0 
relative risk to develop breast cancer and a woman with a sister diagnosed with 
breast cancer has a 2.3 relative risk (57).  Women with a second-degree relative 
diagnosed with breast cancer have a relative risk of 1.5 to develop the same type of 
cancer (57).  All of these risks were increased if the relative was diagnosed at a 
younger age (57). 
One study found that the age of breast cancer onset in a woman with a 
BRCA mutation and a family history of breast cancer can be predicted to a small 
extent by the youngest age of diagnosis within the family and the mean age of 
diagnosis in the family (58).  This effect was slightly significant in BRCA2 carriers 
but not in BRCA1 carriers.  Based on this study, they concluded that it appears that 
an unaffected carrier may have an earlier age at diagnosis if the youngest diagnosis 
in the family is less than 35 years when compared to families were all cases were 
over age 35 (58).  In a study of Polish women with a BRCA1 mutation, they found 
that relatives of women diagnosed with breast cancer had a higher risk of breast 
cancer than relatives of women diagnosed with ovarian cancer (OR=1.7; p=0.03) 
(59).  Some researchers theorize that there may be other modifier genes 
contributing to a greater cancer risk within certain families with a BRCA mutation 
(60).  While the effect of family history on BRCA mutation carriers’ cancer risk does 
not seem to be entirely clear, it does seem to play a role.   
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In conclusion, there are many factors that play a role in the development of 
breast and/or ovarian cancer in the general population.  These factors have not 
been investigated in the development of later-onset breast or ovarian cancer among 
women with a BRCA1 or BRCA2 mutation.  In addition, these factors have not been 
explored among women with a BRCA1 or BRCA2 mutation living at older ages with 
no history of breast or ovarian cancer.  In this study, we attempt to investigate 
reproductive risk factors, hormone receptor status, screening frequencies and 
modalities, risk-reducing surgeries, as well as family history among women with a 
BRCA mutation who did not develop cancer before the age of 50 years and are 
followed at MD Anderson Cancer Center. 
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MATERIALS AND METHODS 
Study Design 
This study was a retrospective chart review of a select population of women with a 
BRCA1 or BRCA2 mutation.  The specific aims of this study were to 1) determine if 
any factors influence whether a woman with a BRCA1 or BRCA2 mutation develops 
breast or ovarian cancer at an early age (<50 years of age) or a later age (≥50 
years) and to identify which factors are important and 2) determine if any factors 
influence whether or not a woman with a BRCA1 or BRCA2 mutation develops 
cancer and determine which factors are important.  The factors observed in this 
study include reproductive factors, BMI, risk-reducing surgeries, and family history.   
 Differences in these factors between women with a BRCA mutation who 
developed breast or ovarian cancer under age 50 and women with a BRCA 
mutation who developed breast or ovarian cancer at age 50 or older were 
investigated.  In addition, differences in these factors between women with a BRCA 
mutation over age 50 with no cancer diagnosis and women with a BRCA mutation 
who developed cancer at age 50 or older were investigated.  The MD Anderson 
Cancer Center electronic medical records (EMR) of this population were reviewed 
and relevant information was extracted and analyzed to identify trends and 
differences in the data.  We hypothesized that there would be differences among 
women who developed breast or ovarian cancer at age 50 or older, women who 
developed breast or ovarian cancer prior to age 50, and women over age 50 who 
had never developed breast or ovarian cancer.  
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Study Approval 
Approval for this study was granted by the University of Texas-Houston 
Health Science Center and the Committee for the Protection of Human Subjects of 
MD Anderson and the on September 1, 2009 and November 5, 2009, respectively. 
 
Study Population 
The study population consisted of 353 MD Anderson Cancer Center patients 
with a BRCA1 or BRCA2 mutation.  Of these women, 20 women are ≥50 years of 
age and have never had a breast or ovarian cancer diagnosis.  Ninety-two women 
were diagnosed with breast or ovarian cancer ≥50 years of age.  There were 241 
MD Anderson Cancer Center patients with a BRCA1 or BRCA2 mutation who had a 
breast or ovarian cancer develop prior to age 50.  Myriad Genetics Laboratory in 
Salt Lake City, Utah performed the genetic testing. 
 
Ascertainment 
Study subjects were ascertained through an IRB approved research 
database at MD Anderson Cancer Center.  The study population included patients 
at MD Anderson between 2/1/1997 and 11/16/2009.  A total of 434 patients were 
identified as potential study participants and their fulfillment of the inclusion criteria 
was confirmed during review of their medical records. Of the 434 patients, 81 
participants were excluded because they did not meet the inclusion criteria for the 
study.  The following individuals were excluded from our data: men, individuals with 
a variant of uncertain significance and no deleterious mutation, and individuals with 
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no BRCA1 or BRCA2 mutation found.  Women who had a variant of uncertain 
significance identified along with a known deleterious BRCA1 or BRCA2 mutation 
were included in our population.  Women with ductal carcinoma in situ (DCIS) were 
not included in our study unless they also had an invasive cancer and we recorded 
their age at diagnosis at the time that they developed the invasive cancer. 
 
Data Collection 
The study population’s medical records at MD Anderson Cancer Center were 
reviewed December 2009 through February 2010.  The information extracted from 
the medical records is presented in table 1. 
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Table 1. Information Obtained through Medical Record Review 
General Information 
Date of birth 
Ethnicity 
Age of last contact with MD Anderson Cancer Center 
BRCA mutation status 
Age at breast or ovarian cancer diagnosis 
Reproductive Risk Factor Information and BMI 
Age at menarche 
Age at menopause (if applicable) 
Age at first full term pregnancy 
Parity (prior to diagnosis) 
Breastfeeding history  
Hormone replacement therapy use 
Oral contraceptive use 
Chemopreventive use (Tamoxifen) 
BMI (Based on height and weight at time of testing) 
Screening History 
Type of screening received (Mammography, Breast MRI, Clinical breast exam, 
Transvaginal ultrasound, or CA-125 blood test) 
Frequency of screening 
Risk-Reducing Surgery 
Type of surgery (Bilateral mastectomy or bilateral salpingo-oophorectomy) 
Age at surgery 
Tumor Pathology Information 
ER and PR Status 
Her2/neu status 
Type of cancer 
Family History Information 
Number of first and second degree relatives with a breast or ovarian cancer 
diagnosis 
Age of cancer diagnosis in first and second degree relatives 
Number of unaffected first and second degree relatives 
 
Statistical Analysis 
STATA 10.0, Microsoft Office Excel 2007, and Microsoft Office Access 2007 
were used to analyze the data that was obtained from the MD Anderson electronic 
medical records.  Descriptive statistics were performed to summarize the content of 
each variable for BRCA1 carriers with cancer under age 50, BRCA1 carriers with 
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cancer over age 50, BRCA1 carriers with no cancer diagnosis, BRCA2 carriers with 
cancer under age 50, BRCA2 carriers with cancer over age 50, and BRCA2 carriers 
with no cancer diagnosis.  All of these variables were analyzed to identify 
differences based on mutations status and we compared women who developed 
cancer at age 50 or older to women who developed cancer before age 50 and those 
who had no cancer diagnosis.  P-values less than 0.05 were considered to be 
statistically significant.   
We used contingency tests (eg. Pearson’s chi square) to compare 
frequencies among our groups.  T-tests were used to analyze normally distributed 
continuous variables between the two groups and Mann-Whitney tests were used to 
compare non-normally distributed continuous variables among the groups.  We 
performed four analyses on most variables and compared the differences between 
the following cohorts as shown in figure 2 and 3.  Women diagnosed with cancer at 
or after age 50 were our referent group for all analyses.  As shown in figure 2, we 
analyzed the differences in BRCA1 or BRCA2 mutation carriers who developed 
cancer before age 50 and those who developed cancer at age 50 or older.  These 
data were stratified by BRCA mutation status.  As shown in figure 3, we analyzed 
differences in women who developed cancer at age 50 or older and women who 
had never developed cancer stratified on their BRCA mutation status. 
 
 
 
 
 
  
Figure 1.  Analysis between women with cancer <
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Figure 2.  Analysis between women
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RESULTS 
The population for our study is shown in figure 2.  BRCA1 and BRCA2 
mutation carriers were analyzed separately for reproductive risk factors, tumor 
characteristics, ethnicity, risk-reducing surgeries, and family history.  There was one 
woman with a BRCA1 and BRCA2 mutation.  She was not included in the analysis 
because the effect of having a mutation in both BRCA genes may impact the risk of 
developing breast or ovarian cancer when compared to women who have a 
mutation in only one of the genes. 
Figure 3. Flowchart for study population 
 
   
 
Average Age of Population 
The average age at diagnosis was not statistically significant between 
BRCA1 and BRCA2 women diagnosed prior to age 50.  There was also no 
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 26 
 
statistically significant difference in age at diagnosis between BRCA1 and BRCA2 
women diagnosed at age 50 or older.  No statistically significant difference was 
found between the current average age of women with a BRCA1 or BRCA2 
mutation who are over age 50 with no cancer diagnosis.  The mean ages for these 
groups, as well as p values for this analysis, are presented in tables 2-4. 
 
Table 2. Age at Diagnosis (<50) based on BRCA mutation status 
Cancer dx. <50 Mean Age (SD) P-Value 
BRCA1 38.87 (6.69) 0.3166 
BRCA2 39.79 (5.92) 
 
 
Table 3. Age at Diagnosis (≥50) based on BRCA mutation status 
Cancer dx. ≥50 Mean Age (SD) P-Value 
BRCA1 57.68 (5.46) 0.2742 
BRCA2 56.41 (5.55) 
 
 
Table 4. Average Current Age based on BRCA mutation status 
≥50 with no 
cancer dx. Mean Age (SD) P-Value 
BRCA1 59.5 (9.56) 0.5046 
BRCA2 56.88 (6.31) 
 
Type of Cancer First Diagnosed 
There was a statistically significant difference (p<0.0001) between the type of 
cancer diagnosed in women before age 50 and at age 50 or older in women with a 
BRCA1 mutation.  Results were similar in women with a BRCA2 mutation 
(p<0.0001).  Women who developed cancer prior to age 50 were more likely to 
have breast cancer whereas those who developed cancer at age 50 or older were 
more likely to have ovarian cancer as their first cancer diagnosis. 
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 The numbers and percentages of women with each type of cancer diagnosis 
are shown in figures 4-5. 
 
Figure 4: Type of cancer first diagnosed in BRCA1 mutation carriers, by age at 
diagnosis 
 
 
Figure 5: Type of cancer first diagnosed in BRCA2 mutation carriers, by age at 
diagnosis 
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REPRODUCTIVE FACTORS 
Mean age Menarche 
There was no difference in the mean age at menarche between women with 
a BRCA1 or BRCA2 mutation who developed cancer prior to age 50 or those who 
had never developed cancer when compared to women who developed cancer at 
age 50 or older.  The mean age at menarche as well as p-values are shown in 
tables 5-6. 
 
Table 5. Age at menarche based on cohort (BRCA1) 
BRCA1 Mean (SD) P-value 
<50 w/ cancer 12.81 (1.59) 0.4522 
≥ 50 w/ cancer * 13.03 (1.78)  
≥50 w/o cancer 12.18 (0.98) 0.1406 
* Referent Group 
 
 
Table 6. Age at menarche based on cohort (BRCA2) 
BRCA2 Mean (SD) P-value 
<50 w/ cancer 12.83 (1.31) 0.5455 
≥ 50 w/ cancer * 12.68 (1.27)  
≥50 w/o cancer 13.13 (1.73) 0.3899 
* Referent Group 
 
 
Mean age Menopause 
 
Women with a BRCA1 or BRCA2 mutation diagnosed with cancer under age 
50 underwent menopause at a statistically significant younger age than those 
diagnosed with cancer at age 50 or older (p<0.0001 for BRCA1; p=0.0007 for 
BRCA2).  In addition, women with a BRCA1 mutation diagnosed with cancer at age 
50 or older underwent menopause at a statistically significant older age than women 
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with a BRCA1 mutation who had never had a cancer diagnosis (p=0.0312).  Women 
with a BRCA2 mutation diagnosed with cancer at age 50 or older had no statistically 
significant difference from those never diagnosed with cancer (p=0.5204).  Figure 6 
shows the average age of menopause among the different cohorts. 
 
Figure 6. Age at menopause based on cohort, by age at diagnosis 
 
 
 
Mean Age at First Full Term Pregnancy 
 
There was no difference in the age at first full-term pregnancy between 
women with a BRCA1 or BRCA2 mutation who developed cancer before age 50 
when compared to those who developed cancer at age 50 or older.  In addition, 
there was no difference between BRCA1 or BRCA2 positive women who developed 
cancer at age 50 or older when compared to women who had not developed 
cancer.  Mean age at first full term pregnancy and p-values are shown in tables 7-8. 
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Table 7. Mean age at first full term pregnancy based on cohort (BRCA1) 
BRCA1 Mean (SD) P-value 
<50 w/ cancer 24.82 (5.75) 0.1081 
≥ 50 w/ cancer * 23.06 (3.93)  
≥50 w/o cancer 24.89 (4.31) 0.2376 
* Referent Group 
 
 
Table 8. Mean age at first full term pregnancy based on cohort (BRCA2) 
BRCA2 Mean (SD) P-value 
<50 w/ cancer 25.64 (5.66) 0.8075 
≥ 50 w/ cancer * 25.35 (5.58)  
≥50 w/o cancer 26.67 (6.66) 0.6999 
* Referent Group 
 
Parity 
There was no difference in parity between women with a BRCA1 or BRCA2 
mutation diagnosed with cancer over age 50 and those never diagnosed with 
cancer.  In addition, there was no statistically significant difference between women 
with a  BRCA1 or BRCA2 mutation who developed cancer prior to age 50 and those 
who developed cancer at age 50 or older.  The median parity and p-values for each 
cohort are shown in tables 9-10. 
 
Table 9.  Median parity based on cohort (BRCA1) 
BRCA1 Group Median (Range) P-value 
<50 w/ cancer 2 (0-8) 0.0710 
≥50 w/ cancer * 2 (0-10)  
≥50 w/o cancer 2 (0-4) 0.5962 
* Referent Group 
 
 
Table 10. Median parity based on cohort (BRCA2) 
BRCA2 Group Median (Range) P-value 
<50 w/ cancer 2 (0-6) 0.0595 
≥50 w/ cancer * 2 (0-7)  
≥50 w/o cancer 2.5 (0-4) 0.8546 
* Referent Group 
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When parity was broken into groups of 0, 1, 2, 3, or ≥4 children, there was no 
statistically significant difference between any of the groups.  The p-value for 
BRCA1 positive women with cancer development prior to age 50 vs. those who 
developed cancer at age 50 or older was 0.6839.  When BRCA1 positive women 
who developed cancer at age 50 or older were compared to those who had never 
developed cancer, the p-value was 0.8508.  When BRCA2 positive women who 
developed cancer prior to age 50 were compared to those who did not develop 
cancer until at age 50 or older, the p-value was 0.5886.  BRCA2 positive women 
who developed cancer at age 50 or older and those who had not developed cancer 
did not differ significantly in respect to their parity group (p=0.8281). 
There was no statistically significant difference between parous women and 
non-parous women with a BRCA1 mutation who developed cancer at age 50 or 
older when compared to those who developed cancer prior to age 50 (p=0.166) or 
those who had not developed cancer (p=0.924).  There was no difference between 
parous and non-parous women with a BRCA2 mutation who developed cancer at 
age 50 or older when compared to those who developed cancer prior to age 50 
(p=0.664) and those who had not yet developed cancer (p=0.309). 
 
Mean time breastfeeding (if parity >0) 
 
There was no statistically significant difference between women with a 
BRCA1 mutation who developed breast cancer prior to age 50 (p=0.3700) or had 
never developed cancer (p=0.9218) when compared to those who had developed 
cancer at age 50 or older.  Women with a BRCA2 mutation who developed cancer 
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prior to age 50 did not differ significantly from women who developed cancer at age 
50 or older (p=0.0805).  There was also no statistical difference in the median 
breastfeeding time period when comparing BRCA2 mutation carriers who 
developed cancer at age 50 or older to those who had never developed cancer 
(0.6371).  The median number of months of breastfeeding and p-values for each 
cohort are presented in tables 11-12. 
 
Table 11.  Median months of breastfeeding based on cohort (BRCA1) 
BRCA1 Group Median (Range) P-value 
<50 w/ cancer 3 (0-44) 0.3700 
≥50 w/ cancer * 1.5 (0-9)  
≥50 w/o cancer 4 (0-10) 0.9218 
* Referent Group 
 
Table 12.  Median months of breastfeeding based on cohort (BRCA2) 
BRCA2 Group Median (Range) P-value 
<50 w/ cancer 4 (0-24) 0.0805 
≥50 w/ cancer * 3 (0-18)  
≥50 w/o cancer 0 (0) 0.6371 
* Referent Group 
  
There was no difference between the cohorts when comparing whether or 
not they had ever breastfed their children.  The number of women who breastfed 
their children and the p-values associated are shown in tables 13-14. 
 
Table 13. Breastfeeding status based on cohort (BRCA1) 
Breastfeeding 
BRCA1 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=10 
n, (%) 
Total n=48 P-value 
n, (%) 
Total 
n=3 
P-value 
Yes 6 (60) 34 (71) 0.501 2 (67) 0.835 No 4 (40) 14 (29) 1 (33) 
* Referent Group 
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Table 14. Breastfeeding status based on cohort (BRCA2) 
Breastfeeding 
BRCA2 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
 
≥50 w/out cancer 
 
n, (%) 
Total n=11 
n, (%) 
Total n=23 P-value 
n, (%) 
Total 
n=0 
P-value 
Yes 7 (64) 15 (65) 0.928 0 (0) 0.217 No 4 (36) 8 (35) 1 (100) 
* Referent Group 
 
HRT and OCP Use 
 
Oral contraceptive use did not affect the development of cancer among 
BRCA1 or BRCA2 women who developed cancer at age 50 or older when 
compared to those who developed cancer prior to age 50 or had never developed 
cancer.  The numbers and percentages of women who used oral contraceptives are 
shown in tables 15-16. 
 
Table 15. Oral Contraceptive use based on cohort (BRCA1) 
OCP Use 
BRCA1 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=33 
n, (%) 
Total n=151 P-value 
n, (%) 
Total 
n=10 
P-value 
Yes 25 (76) 120 (79) 0.636 6 (60) 0.186 No 8 (24) 31 (21) 4 (40) 
* Referent Group 
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Table 16. Oral contraceptive use based on cohort (BRCA2) 
OCP Use 
BRCA2 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=46 
n, (%) 
Total n=60 P-value 
n, (%) 
Total 
n=8 
P-value 
Yes 34 (74) 49 (82) 0.337 7 (88) 0.407 No 12 (26) 11 (18) 1 (12) 
* Referent Group 
 
Women with a BRCA1 or BRCA2 mutation who developed cancer at age 50 
or older were more likely to have taken a hormone replacement therapy than 
women who developed cancer prior to age 50.  There was no difference in women 
with a BRCA1 or BRCA2 mutation diagnosed at age 50 or older when compared to 
those who had never developed cancer.  The numbers and percentages of women 
who used HRT are shown in tables 17-18. 
 
Table 17. HRT use based on cohort (BRCA1) 
HRT Use 
BRCA1 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=36 
n, (%) 
Total n=118 P-value 
n, (%) 
Total 
n=10 
P-value 
Yes 20 (56) 20 (17) 
<0.001 7 (70) 0.412 No 16 (44) 98 (83) 3 (30) 
* Referent Group 
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Table 18. HRT use based on cohort (BRCA2) 
HRT Use 
BRCA2 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=46 
n, (%) 
Total n=51 P-value 
n, (%) 
Total 
n=7 
P-value 
Yes 27 (59) 8 (16) 
<0.001 5 (71) 0.521 No 19 (41) 43 (84) 2 (29) 
* Referent Group 
 
BMI 
No statistically significant differences in mean BMI were found between 
women diagnosed before age 50 and those diagnosed at age 50 or older with a 
BRCA1 or BRCA2 mutation.  There were also no statistically significant differences 
between women diagnosed with cancer at age 50 or older and those with no cancer 
diagnosis.  The average BMI for each group, as well as p values, are shown in 
Figure 7. 
 
Figure 7. Average BMI and p-values, by age at diagnosis 
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SCREENING FREQUENCY AND MODALITY 
There was a statistically significant difference between the number of women 
with a BRCA1 mutation who received mammograms when comparing those 
diagnosed with cancer prior to age 50 and those who developed cancer at age 50 
or older (p=0.009).  Women who developed their cancer at a later age were more 
likely to have undergone mammography than those who developed cancer at an 
earlier age.  There was no difference between women with a BRCA1 or BRCA2 
mutation who developed cancer at age 50 or older and those who had never 
developed cancer (p=0.448, 0.896).  In women with a BRCA2 mutation, there was 
no significant difference in whether or not the woman had received a mammogram 
when comparing women who developed cancer prior to age 50 to those who 
developed cancer at age 50 or older (p=0.535). 
There was a statistically significant difference in women with a BRCA1 or 
BRCA2 mutation who had received a breast MRI when comparing women who 
developed cancer prior to age 50 to those who developed cancer at age 50 or older 
(p=0.017, <0.001).  Women diagnosed at age 50 or older were more likely to have 
had a breast MRI than those who developed cancer before age 50.  There was no 
statistically significant difference in BRCA1 or BRCA2 positive women who 
developed cancer at age 50 or older when compared to those with no cancer 
diagnosis (p=0.095, 0.788). 
Women with a BRCA1 mutation with no cancer development were less likely 
to have had a clinical breast exam than those who had developed cancer at age 50 
or older (p=0.003).  There was no statistically significant difference between BRCA1 
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and BRCA2 women diagnosed with cancer at an earlier age when compared to 
those diagnosed at a younger age when observing whether or not they had a 
clinical breast exam performed (p=0.585, 0.532).  In addition, there was no 
difference between BRCA2 women who developed cancer at age 50 or older when 
compared to those who had no cancer (p=0.939). 
There was no difference in the number of BRCA1 or BRCA2 positive women 
who had had a CA-125 blood test when comparing those who developed cancer 
prior to age 50 or those who had never developed cancer to women who developed 
cancer at age 50 or older.  P-value for BRCA1 positive women who developed 
cancer prior to age 50 when compared to those who developed cancer at age 50 or 
older was 0.378.  When comparing those with a BRCA1 mutation who developed 
cancer at age 50 or older to those who had never developed cancer, the p-value 
was 0.252.  In women with a BRCA2 mutation who developed cancer at a later age, 
the p-value was 0.131 when compared to those who developed cancer at an earlier 
age.  The p-value when comparing women with a BRCA2 mutation who had never 
developed cancer to those who had developed cancer at age 50 or older was 0.397. 
There was no difference in the number of women with a BRCA1 or BRCA2 
mutation who had had a transvaginal ultrasound when comparing women who 
developed cancer at a later age to women who developed cancer at a younger age 
or who had never had a cancer diagnosis (p=0.872, 0.103, 0.842, 0.726). 
The percentage of women who underwent the different screening procedures 
are shown in figures 8-9. 
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Figure 8. Percentage of women undergoing screening procedures based on cohort 
(BRCA1), by age at diagnosis 
 
 
 
Figure 9.  Percentage of women undergoing screening procedures based on cohort 
(BRCA2), by age at diagnosis 
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There was no difference in the screening frequency when comparing women 
with a BRCA1 or BRCA2 mutation diagnosed with cancer at age 50 or older to 
those who had never developed cancer (p=0.738, 0.825).  Women with a BRCA1 or 
BRCA2 mutation who developed cancer at age 50 or older had a different 
distribution of screening frequency when compared to women who developed 
cancer prior to age 50 (p= 0.006, 0.009).  The number of women who performed 
screening at certain time intervals are shown in tables 19-20. 
 
Table 19. Screening frequency based on cohort (BRCA1) 
Screening 
Frequency 
(BRCA1) 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=29 
n, (%) 
Total n=67 P-value  
n, (%) 
Total 
n=11 
P-value  
>Once per year 15 (52) 12 (18) 
0.006 
6 (55) 
0.738 Annually 11 (38) 47 (70) 5 (45) 
<Once per year 2 (7) 7 (10) 0 (0) 
Never 1 (3) 1 (2) 0 (0) 
* Referent Group 
 
Table 20. Screening frequency based on cohort (BRCA2) 
Screening 
Frequency 
(BRCA2) 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=39 
n, (%) 
Total n=34 P-value  
n, (%) 
Total 
n=7 
P-value  
>Once per year 16 (41) 3 (9) 
0.009 
3 (43) 
0.825 Annually 20 (51) 24 (70) 3 (43) 
<Once per year 3 (8) 5 (15) 1 (14) 
Never 0 (0) 2 (6) 0 
* Referent Group 
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CHEMOPREVENTION USE 
There was not enough data to determine the differences in tamoxifen use 
between women with a BRCA1 or BRCA2 mutation who had developed cancer 
before or at age 50 or older.  This information was not available in the medical 
records for the majority of these women.  We did find that of the women who had 
not developed cancer, 56% of BRCA1 positive women and 88% of BRCA2 positive 
women had used tamoxifen.   
 
RISK-REDUCING PROCEDURES 
There was no difference in whether or not women with a BRCA1 mutation 
underwent risk-reducing surgery when comparing women diagnosed at age 50 or 
older to those diagnosed prior to age 50.  Women with a BRCA2 mutation who 
developed cancer under age 50 were more likely to undergo risk-reducing surgery 
than those who developed cancer at age 50 or older.  Women with a BRCA1 or 
BRCA2 mutation who had no cancer history were more likely to have undergone 
risk-reducing surgery than those who had developed cancer at age 50 or older.  The 
numbers and percentages of women who underwent risk-reducing mastectomy or 
BSO are shown in tables 21-22. 
The vast majority of women underwent risk-reducing BSO.  Four women with 
a BRCA1 mutation underwent a prophylactic mastectomy; three diagnosed prior to 
age 50 and one diagnosed at age 50 or older.  There were only two women who 
underwent both a prophylactic bilateral mastectomy and BSO; both were over age 
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50 with no cancer diagnosis, one of whom had a BRCA1 mutation and one who had 
a BRCA2 mutation.   
  
Table 21. Number of women who underwent risk-reducing mastectomy or BSO 
based on cohort (BRCA1) 
Underwent 
Surgery 
(BRCA1) 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=40 
n, (%) 
Total n=169 P-value 
n, (%) 
Total 
n=11 
P-value 
Yes 13 (32.5) 86 (51) 0.092 9 (82) 0.009 No 27 (67.5) 83 (49) 2 (18) 
* Referent Group 
 
Table 22. Number of women who underwent risk-reducing mastectomy or BSO 
based on cohort (BRCA2) 
Underwent 
Surgery 
(BRCA2) 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=51 
n, (%) 
Total n=67 P-value 
n, (%) 
Total 
n=8 
P-value 
Yes 13 (25) 35 (52) 0.003 7 (87.5) <0.001 No 38 (75) 32 (48) 1 (12.5) 
* Referent Group 
 
 
Women with a BRCA1 or BRCA2 mutation diagnosed with cancer under age 
50 underwent risk-reducing surgeries at a statistically significant younger age than 
those diagnosed at age 50 or older (p<0.0001 and 0.0149, respectively).  There 
was no difference between the age of risk-reducing surgery for women over 50 with 
no cancer and those diagnosed at age 50 or older.  The mean ages at risk-reducing 
surgery and p-values are shown in tables 23-24. 
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Table 23. Mean age at risk-reducing mastectomy or BSO based on cohort (BRCA1) 
BRCA1 Mean (SD) P-value 
<50 w/ cancer 43.77 (7.01) <0.0001 
≥ 50 w/ cancer * 54.86 (12.03)  
≥50 w/o cancer 51.78 (11.20) 0.5452 
* Referent Group 
 
 
Table 24. Mean age at risk-reducing mastectomy or BSO based on cohort (BRCA2) 
BRCA2 Mean (SD) P-value 
<50 w/ cancer 45.32 (9.15) 0.0149 
≥ 50 w/ cancer * 52.23 (6.06)  
≥50 w/o cancer 53.57 (6.63) 0.6530 
* Referent Group 
 
TUMOR CHARACTERISTICS 
There was no statistically significant difference in ER status among women 
with a BRCA1 mutation who were diagnosed with breast cancer prior to age 50 
when compared to those who developed breast cancer at age 50 or older.  Women 
with a BRCA2 mutation who developed cancer prior to age 50 were more likely to 
have an ER positive breast cancer than those who developed cancer at age 50 or 
older.  The numbers of women with ER positive and ER negative breast tumors are 
shown in tables 25-26. 
 
Table 25. ER status based on cohort (BRCA1) 
BRCA1 Group 
<50 w/ cancer 
n, (%) 
Total n=96 
≥50 w/ cancer 
n, (%) 
Total n=18 
P-value 
ER positive 24 (25) 8 (44) 0.092 ER negative 72 (75) 10 (56) 
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Table 26. ER status based on cohort (BRCA2) 
BRCA2 Group 
<50 w/ cancer 
n, (%) 
Total n=43 
≥50 w/ cancer 
n, (%) 
Total n=24 
P-value 
ER positive 33 (77) 9 (37) 0.001 ER negative 10 (23) 15 (63) 
 
The PR status of breast tumors in women with a BRCA1 mutation who 
developed breast cancer prior to age 50 was not statistically significant when 
compared to women who developed breast cancer at age 50 or older.  Women with 
a BRCA2 mutation who developed cancer prior to age 50 were more likely to have a 
PR positive breast cancer when compared to those with cancer at age 50 or older.  
The numbers of women with PR positive and PR negative breast tumors are shown 
in tables 27-29. 
 
Table 27. PR status based on cohort (BRCA1) 
BRCA1 Group 
<50 w/ cancer 
n, (%) 
Total n=92 
≥50 w/ cancer 
n, (%) 
Total n=17 
P-value 
PR positive 21 (23) 5 (29) 0.558 PR negative 71 (77) 12 (71) 
 
 
Table 28. PR status based on cohort (BRCA2) 
BRCA2 Group 
<50 w/ cancer 
n, (%) 
Total n=41 
≥50 w/ cancer 
n, (%) 
Total n=24 
P-value 
PR positive 31 (76) 7 (29) 
<0.001 PR negative 10 (24) 17 (71) 
 
There was no difference in the Her2/neu status when comparing women with 
a BRCA1 or BRCA2 mutation diagnosed with cancer under age 50 to those 
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diagnosed at age 50 or older.  The numbers of women with Her2/neu positive and 
Her2/neu negative breast tumors are presented in tables 29-30. 
 
Table 29. Her2/neu status based on cohort (BRCA1) 
BRCA1 Group 
<50 w/ cancer 
n, (%) 
Total n=72 
≥50 w/ cancer 
n, (%) 
Total n=14 
P-value 
Her2/neu positive 6 (8) 2 (14) 0.483 Her2/neu negative 66 (92) 12 (86) 
 
Table 30. Her2/neu status based on cohort (BRCA2) 
BRCA2 Group 
<50 w/ cancer 
n, (%) 
Total n=34 
≥50 w/ cancer 
n, (%) 
Total n=20 
P-value 
Her2/neu positive 6 (18) 1 (5) 0.182 Her2/neu negative 28 (82) 19 (95) 
 
ETHNICITY 
There was no difference in the ethnicity distribution when women with a 
BRCA1 or BRCA2 mutation who developed cancer at age 50 or older were 
compared to those who had never developed cancer.  There was a statistically 
significant difference in the distribution of ethnicity between women with a BRCA1 
or BRCA2 mutation who developed cancer prior to age 50 when compared to 
women who developed cancer at age 50 or older (p=0.006 for BRCA1 and p=0.019 
for BRCA2).  Ashkenazi Jewish women with a BRCA1 mutation are more likely to 
have their cancer diagnosed at age 50 or older when compared to Caucasian 
women with a BRCA1 mutation (p=0.002).  In addition, women with a BRCA1 
mutations whose race was listed as “other” were found to be more likely to have 
their cancer diagnosed at age 50 or older when compared with Caucasian women 
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(p=0.026).  Hispanic women with a BRCA2 mutation were more likely to be 
diagnosed with cancer prior to age 50 when compared to Caucasian women 
(p=0.008). 
The number and percentage of women from each ethnicity category are 
shown based on their cohort in figures 10-11. 
 
Figure 10.  Ethnicity based on cohort (BRCA1), by age at diagnosis 
 
 
Figure 11. Ethnicity based on cohort (BRCA2), by age at diagnosis 
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FAMILY HISTORY 
For family history information, we collected data about first and second 
degree relatives (FDR and SDR). 
First Degree Relatives in BRCA1 Carriers 
Women with a BRCA1 mutation diagnosed at age 50 or older were more 
likely to have 0 or 1 affected first degree relative whereas those who had not 
developed cancer were more likely to have 2 or 3 first degree relatives.  We did not 
find any statistically significant results when comparing the percentage of family 
members diagnosed with a breast or ovarian cancer among the BRCA1 mutation 
carriers. 
The number of families and number and percentage of first degree relatives 
with a breast or ovarian cancer diagnosis are shown in tables 31-32. 
 
Table 31. First degree relatives with breast or ovarian cancer based on cohort 
(BRCA1) 
Number of 
Families with N 
cases of Breast 
or Ovarian 
Cancer in FDR 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=41 
n, (%) 
Total n=153 P-value  
n, (%) 
Total 
n=11 
P-value  
n=0 10 (24) 49 (32) 
0.053 
0 (0) 
0.001 
n=1 18 (44) 73 (48) 1 (9) 
n=2 13 (32) 21 (14) 8 (73) 
n=3 0 (0) 8 (5) 2 (18) 
n≥4 0 (0) 2 (1) 0 (0) 
* Referent Group 
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Table 32.  Percentage of first degree relatives with breast or ovarian cancer based 
on cohort (BRCA1) 
Percentage of 
FDRs with 
Breast or 
Ovarian 
Cancers 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=41 
n, (%) 
Total n=153 P-value  
n, (%) 
Total 
n=11 
P-value  
0% 10 (24) 49 (32) 
0.094 
0 (0) 
0.054 
1-24% 17 (42) 48 (31) 4 (36) 
25-49% 11 (27) 24 (16) 6 (55) 
50-74% 0 (0) 12 (8) 1 (9) 
100% 3 (7) 20 (13) 0 (0) 
* Referent Group 
 
There was a statistically significant difference in whether or not a woman with 
a BRCA1 mutation had first degree relatives diagnosed with breast or ovarian 
cancer prior to age 50 when comparing women who developed cancer at age 50 or 
older to those who had never had cancer (p=0.030).  This data is shown in table 33.  
We did not find any statistical significance when comparing whether or not each of 
the groups had a first degree relative diagnosed with breast or ovarian cancer after 
the age of 50.  The number of women with first degree relatives diagnosed with 
breast or ovarian cancer under age 50 and p-values are presented in table 33.  The 
number of women with first degree relatives diagnosed with breast or ovarian 
cancer over the age of 50 and p-values are presented in table 34. 
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Table 33. Cancer diagnoses <50 years of age in first degree relatives based on 
cohort (BRCA1)  
First Degree 
Relatives 
Diagnosed 
Under Age 50 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=38 
n, (%) 
Total n=137 P-value  
n, (%) 
Total 
n=10 
P-value  
Yes 25 (66) 79 (58) 0.367 10 (100) 0.030 No 13 (34) 58 (42) 0 (0) 
* Referent Group 
 
Table 34. Cancer diagnoses ≥50 years of age in first degree relatives based on 
cohort (BRCA1) 
First Degree 
Relatives 
Diagnosed ≥50 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=38 
n, (%) 
Total n=121 P-value  
n, (%) 
Total 
n=11 
P-value  
Yes 14 (37) 37 (31) 0.471 3 (27) 0.557 No 24 (63) 84 (69) 8 (73) 
* Referent Group 
 
First Degree Relatives in BRCA2 Carriers 
When comparing BRCA2 mutation carriers who developed cancer at age 50 
or older to those who developed cancer prior to age 50, we found a statistically 
significant difference between the number of first-degree relatives diagnosed with 
breast or ovarian cancer.  When we compared these data and looked at the 
percentage of family members diagnosed with a breast or ovarian cancer, we still 
found statistical significance between women with a BRCA2 mutation who 
developed cancer prior to age 50 and those who developed cancer at age 50 or 
older.  The number of families and number and percentage of first degree relatives 
with a breast or ovarian cancer diagnosis are shown in tables 35-36. 
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Table 35. Number of first-degree relatives with breast or ovarian cancer based on 
cohort (BRCA2) 
Number of 
Families with N 
cases of Breast 
or Ovarian 
Cancer in FDR 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=49 
n, (%) 
Total n=66 P-value  
n, (%) 
Total 
n=8 
P-value  
n=0 10 (20) 35 (53) 
0.005 
1 (12.5) 
0.319 
n=1 29 (59) 21 (32) 3 (37.5) 
n=2 8 (17) 7 (11) 3 (37.5) 
n=3 1 (2) 3 (4) 1 (12.5) 
n≥4 1 (2) 0 (0) 0 (0) 
* Referent Group 
 
Table 36. Percentage of first degree relatives with breast or ovarian cancer 
diagnosis based on cohort (BRCA2) 
Percentage of 
Families with N 
cases of Breast 
or Ovarian 
Cancer in FDR 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=49 
n, (%) 
Total n=66 P-value  
n, (%) 
Total 
n=8 
P-value  
0% 10 (20) 35 (53) 
0.001 
1 (12.5) 
0.527 
1-24% 24 (49) 12 (18) 3 (37.5) 
25-49% 9 (19) 7 (11) 3 (37.5) 
50-74% 2 (4) 4 (6) 1 (12.5) 
100% 4 (8) 8 (12) 0 (0) 
* Referent Group 
 
There was no difference between women with a BRCA2 mutation who 
developed cancer at age 50 or older and those who developed cancer prior to age 
50 when investigating whether they had any first degree relatives with a breast or 
ovarian cancer diagnosis under age 50.  We found statistical significance when 
comparing BRCA2 mutation carriers who developed cancer prior to age 50 to those 
who developed cancer at age 50 or older when comparing whether or not they had 
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a first degree relative diagnosed with breast or ovarian cancer at age 50 or older.  
The number of women with first degree relatives diagnosed with breast or ovarian 
cancer under age 50 and p-values are presented in table 37.  The number of 
women with first degree relatives diagnosed with breast or ovarian cancer over the 
age of 50 and p-values are presented in table 38. 
 
Table 37. Cancer diagnoses <50 based on cohort (BRCA2) 
First Degree 
Relatives 
Diagnosed 
Under Age 50 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=43 
n, (%) 
Total n=58 P-value  
n, (%) 
Total 
n=5 
P-value  
Yes 17 (40) 26 (45) 0.595 3 (60) 0.380 No 26 (60) 32 (55) 2 (40) 
* Referent Group 
 
 
Table 38. Cancer diagnoses ≥50 based on cohort (BRCA2) 
First Degree 
Relatives 
Diagnosed ≥50 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=44 
n, (%) 
Total n=54 P-value  
n, (%) 
Total 
n=7 
P-value  
Yes 26 (59) 7 (13) 
<0.001 4 (57) 0.923 No 18 (41) 47 (87) 3 (43) 
* Referent Group 
 
Second Degree Relatives 
When looking at second degree relatives who developed breast or ovarian 
cancer, there was no difference between BRCA1 or BRCA2 positive women who 
developed cancer prior to age 50 or had never developed cancer when compared to 
those who developed cancer after the age of 50.  The number of first-degree 
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relatives with a breast or ovarian cancer and p-values are presented in tables 39-
40. 
 
Table 39. Number of first degree and second degree relatives with breast or ovarian 
cancer based on cohort (BRCA1) 
Number of 
Families with N 
cases of Breast 
or Ovarian 
Cancer in FDR 
& SDR 
≥50 w/ 
cancer * 
 
<50 w/ cancer 
 
≥50 w/out cancer 
 
n, (%) 
Total n=41 
n, (%) 
Total n=163 P-value  
n, (%) 
Total 
n=12 
P-value  
n=0 2 (5) 19 (12) 
0.507 
0 (0) 
0.312 
n=1 13 (32) 51 (31) 1 (8) 
n=2 15 (37) 47 (29) 6 (50) 
n=3 6 (15) 33 (20) 4 (34) 
n≥4 5 (12) 13 (8) 1 (8) 
* Referent Group 
 
Table 40. Number of first degree and second degree relatives with breast or ovarian 
cancer based on cohort (BRCA2) 
Number of 
Families with N 
cases of Breast 
or Ovarian 
Cancer in FDR 
& SDR 
≥50 w/ 
cancer * 
<50 w/ cancer ≥50 w/out cancer 
n, (%) 
Total n=49 
n, (%) 
Total n=70 P-value  
n, (%) 
Total 
n=8 
P-value  
n=0 3 (6) 15 (21) 
0.246 
0 (0) 
0.366 
n=1 15 (31) 20 (29) 1 (12.5) 
n=2 17 (35) 19 (27) 4 (50) 
n=3 6 (12) 7 (10) 0 (0) 
n≥4 8 (16) 9 (13) 3 (37.5) 
* Referent Group 
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DISCUSSION 
To our knowledge, there has been no previous research specifically 
evaluating the older population of women with a BRCA1 or BRCA2 mutation who do 
not have cancer or who developed cancer at a later age (age 50 or older).  The aim 
of this study was to evaluate reproductive risk factors, family history, BMI, and 
tumor pathology among women with a BRCA1 or BRCA2 mutation who developed 
breast or ovarian cancer age 50 or older and determine if there were statistically 
significant differences between any of these factors when compared to women with 
a BRCA1 or BRCA2 mutation who developed cancer prior to age 50.  An additional 
aim of this study was to evaluate reproductive risk factors, family history, BMI, and 
tumor pathology among women with a BRCA1 or BRCA2 mutation who are over the 
age of 50 and have not developed cancer and determine if there were any 
significant differences in these factors when compared to women with a BRCA1 or 
BRCA2 mutation who developed cancer at age 50 or older.  The goal of the 
analyses was to determine whether or not there are factors in BRCA1 or BRCA2 
positive women that determine whether a woman develops early or late onset 
breast cancer as well as to determine whether there are factors that determine 
whether or not a woman with a BRCA1 or BRCA2 mutation ever develops breast or 
ovarian cancer. 
Women with a BRCA1 or BRCA2 mutation who developed cancer prior to 
age 50 were more likely to develop breast cancer as their first cancer diagnosis 
than those who developed cancer at age 50 or older.  The vast majority of women 
diagnosed under age 50 (79% of BRCA1 and 96% of BRCA2 mutation carriers) 
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were diagnosed with breast cancer whereas only 42% of BRCA1 and 53% of 
BRCA2 mutation carriers diagnosed at age 50 or older were diagnosed with breast 
cancer.  Ovarian cancer was more likely to be diagnosed in the women who 
developed cancer at age 50 or older than those who developed cancer prior to age 
50.  The fact that women are more likely to be diagnosed with ovarian cancer at age 
50 or older is consistent with the literature, as ovarian cancer often develops at an 
older age (6, 61), however it is interesting to note that women who developed 
cancer at age 50 or older were had an approximately equal likelihood to develop 
ovarian cancer as they did to develop breast cancer.  In women with a BRCA1 or 
BRCA2 mutation, the lifetime risk of breast cancer is greater than that of ovarian 
cancer (3-6, 61), however from this study, it appears as though at age 50 or older, 
the chance for a woman with a BRCA1 or BRCA2 mutation to develop breast 
cancer is approximately the same as that to develop ovarian cancer. 
 
REPRODUCTIVE RISK FACTORS 
Age at Menarche 
Age at menarche did not show statistical significance between any of the 
groups in our study.  This is consistent with one previous study that did not find an 
association between age at menarche and breast cancer risk in BRCA1 or BRCA2 
carriers (10).  Other studies have found that a later age of menarche is associated 
with a decreased breast cancer risk in BRCA1 mutation carriers (9, 15), however 
this was not observed in our population.  Our study suggests that the age at 
menarche does not affect whether or not a woman with a BRCA1 or BRCA2 
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mutation will develop breast or ovarian cancer before age or after age 50.  It also 
suggests that age at menarche does not determine whether a woman will develop 
cancer at age 50 or older or not develop cancer at all.   
 
Age at Menopause 
Women with a BRCA1 or BRCA2 mutation who developed cancer prior to 
age 50 underwent menopause at a statistically significant younger age than women 
who developed cancer at age 50 or older.  Those with a BRCA1 mutation who 
developed cancer at age 50 or older underwent menopause at an average age of 
44 years and those who developed cancer after 50 underwent menopause at an 
average age of 49.  This is not consistent with current literature.  Early age at 
menopause is associated with a decreased risk of breast and ovarian cancer (7, 10, 
12).  We would expect that women diagnosed with cancer at age 50 or older would 
have an earlier age of menopause.  The reason for the difference in our study is 
likely that women diagnosed under age 50 underwent menopause earlier due to 
chemotherapy or surgery.  When observing age at prophylactic surgery, women 
diagnosed with cancer at a younger age were more likely to undergo prophylactic 
BSO at a younger age when compared to those who developed cancer at a later 
age.  When ascertaining the age at menopause, we did not distinguish between 
women who had naturally undergone menopause from women whose menopause 
was surgically or chemotherapy induced.  This likely accounts for the difference 
seen in ages at menopause between women diagnosed with cancer at a younger 
age.  Because these women were more likely to have undergone chemotherapy or 
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surgery that induced menopause, these women went through menopause at a 
statistically significant younger age.  Future studies should investigate whether the 
natural age at menopause differs between women who developed cancer at a late 
vs. early age or those who have not developed cancer. 
Women with a BRCA1 mutation who developed cancer at age 50 or older 
went through menopause at an average age of 49 while those who had never 
developed cancer underwent menopause at an average age of 44.  Women who 
developed cancer at a later age underwent menopause at a statistically significant 
older age than those with no cancer diagnosis.  This is not consistent with the 
current literature.  It is not known why this difference was seen in BRCA1 mutation 
carriers, but not in BRCA2 mutation carriers.  In BRCA2 carriers, the average age at 
menopause in women who developed cancer at age 50 or older was 49 and those 
who had never developed cancer underwent menopause at an average age of 50.  
This is more consistent with the current literature.  We are unable to explain the 
difference in age at menopause between BRCA1 mutation carriers whose cancer 
developed at age 50 or older and those who had never developed cancer.  This is a 
factor that needs further investigation.   
 
Age at First Full-Term Pregnancy 
Age at first full-term pregnancy did not appear to have an effect on whether a 
woman with a BRCA1 or BRCA2 mutation had early or late onset cancer.  It also did 
not appear to have an effect on whether or not a woman with a BRCA1 or BRCA2 
mutation developed cancer at age 50 or older or had never developed cancer.  The 
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literature about age at first full-term pregnancy in women with a BRCA1 or BRCA2 
mutation is not consistent.  Some studies have found that early age at full-term birth 
was not protective against breast cancer in women with a BRCA1 or BRCA2 
mutation (14).  Other studies have shown that later ages of first childbirth was 
associated with an increased risk of breast cancer in BRCA2 mutation carriers (15).  
Our study did not find any statistically significant differences between the groups, 
suggesting that age at first full-term pregnancy does not significantly affect whether 
or not a woman will develop cancer at an early or later age or whether she will 
develop cancer during her lifetime. 
 
Parity 
Women with a BRCA1 mutation who developed cancer at age 50 or older 
had more children (2.73) than those who developed cancer prior to age 50 (1.96) 
and   Women with a BRCA2 mutation who developed cancer at age 50 or older had 
more children (2.33) than those who developed cancer prior to age 50 (1.86).  While 
these results were not statistically significant, they did approach significance for 
individuals with a BRCA1 mutation (p=0.0710 for BRCA1 and p=0.595 for BRCA2).  
Previous studies have found that the risk for breast and ovarian cancer in women 
with a BRCA1/2 mutation decreases as parity increases (9, 15-17), however we did 
not find any statistical significance in our data.  We did not find any differences in 
parous and non-parous women with a BRCA1 or BRCA2 mutation who developed 
cancer at age 50 or older when compared to those who developed cancer prior to 
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age 50 or who had never developed cancer.  This has been seen in previous 
studies (15).   
There was a woman with a BRCA1 mutation diagnosed at age 50 or older 
who had 10 children.  Because of the possibility of skewed data, we analyzed parity 
in such a way that those with four or more children were put into one group.  When 
we attempted to correct for this possibility of skewed data, there was no statistical 
significance between any of the groups and the p-values did not approach 
significance.  Parity does not appear to have an effect on whether or not a woman 
with a BRCA1 or BRCA2 mutation will develop cancer at an earlier or later age.  It 
also does not seem to have an effect on whether a woman develops cancer at age 
50 or older or does not develop cancer.  Because we saw statistically significant 
values or values approaching significance when looking at total parity for the 
groups, it may be that having many children (more than 4) has an effect on breast 
or ovarian cancer risk, however the data may be skewed in our analysis. 
 
Breastfeeding 
There was no statistical difference in the mean time of breastfeeding among 
BRCA1 or BRCA2 mutation carriers who developed cancer prior to age 50 when 
compared to those who developed cancer at age 50 or older.  There was also no 
difference in women who had never developed cancer when compared to those 
who developed cancer at age 50 or older.  We also investigated whether there was 
a difference in any of the groups when comparing whether or not they had ever 
breastfed at all and found no significance between any of the groups.  From our 
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study, it does not appear that breastfeeding has an impact on the breast or ovarian 
cancer risk in women with a BRCA1 or BRCA2 mutation.  This is consistent with 
previous studies (9, 11, 15, 18). 
 
Overall Reproductive Factors 
Many of the reproductive factors that are known to have an effect on a 
woman’s breast or ovarian cancer risk do not seem to have an effect on this risk in 
BRCA1 or BRCA2 mutation carriers.  Parity may have some effect, however it 
seems as though this effect may only be evident if a woman has more than 4 
children.  The fact that reproductive factors do not appear to have an effect on 
whether a woman is diagnosed with cancer at an early or later age likely means that 
the woman’s risk from her BRCA1 or BRCA2 mutation overrides any protective 
effect that reproductive factors may have.  
 
OCP AND HRT USE 
We did not find any difference in whether or not a woman had used oral 
contraceptives when comparing women who developed cancer at age 50 or older to 
those who developed cancer before age 50 or had never developed cancer.  It does 
not appear, from our study, that oral contraceptive use affects breast or ovarian 
cancer development in BRCA1 or BRCA2 mutation carriers. 
We found that women who developed cancer at age 50 or older were more 
likely to have used hormone replacement therapy than women who developed 
cancer prior to age 50.  This is likely due to the ascertainment of the two groups.  
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Most of the women who developed cancer under age 50 had not yet gone through 
menopause, therefore they were less likely to have needed hormone replacement 
therapy.  No conclusions can be drawn about hormone replacement therapy use 
and breast and ovarian cancer development from this data.   
 
BMI 
While there were no statistically significant differences in women with a 
BRCA1 or BRCA2 mutation who developed cancer at age 50 or older when 
compared to those who developed cancer prior to age 50 or had never developed 
cancer, we did note that women who were over age 50 with no cancer diagnosis 
had a lower average BMI than the other groups.  While this difference was not 
statistically significant, it was consistent among the BRCA1 and BRCA2 groups.  
Previous literature has shown that women in the general population with a lower 
BMI after menopause have a decreased risk of breast cancer (27, 28).  For this 
study, BMI was ascertained at the time the individual presented to MD Anderson for 
their genetic testing.  Women diagnosed at a younger age may have had their 
genetic testing performed at a younger age compared to women who were 
diagnosed at an older age, therefore the data may be somewhat biased.  A 
woman’s body weight fluctuation throughout life may have more impact on her 
breast cancer diagnosis than BMI at a specific time in her life (29, 62), therefore a 
more accurate way to assess whether BMI impacts breast or ovarian cancer may be 
to record a woman’s BMI at different time points in her life. 
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SCREENING 
We observed screening frequency and screening modalities of women with a 
BRCA1 or BRCA2 mutation prior to their cancer diagnosis.  In looking at screening 
frequency, we found a difference in frequency of screening when comparing women 
with a BRCA1 or BRCA2 mutation who developed cancer at age 50 or older to 
those who developed cancer prior to age 50.  Women who developed cancer at age 
50 or older underwent more frequent screening than those who developed cancer 
prior to age 50.  This is likely because many of the women who were diagnosed 
under age 50 were diagnosed prior to 40 years of age and the breast cancer 
screening recommendations for women in the general population is to begin 
mammography at age 40.  Because many of these women were not yet 40 years of 
age, it is likely that their first mammogram was for diagnostic purposes, not for 
screening purposes.  In addition, some of the women who developed cancer under 
age 50 may not have had knowledge of their BRCA mutation prior to their cancer 
diagnosis, so they were likely not undergoing the increased surveillance 
recommendations that have been developed for women with a BRCA1 or BRCA2 
mutation.  Women who developed cancer at age 50 or older were likely already 
getting their annual breast cancer screening, even without knowledge of their BRCA 
mutation, due to the screening recommendations that are in place for the general 
population. 
There was no difference in screening frequency between women who 
developed breast cancer at age 50 or older and those who had never developed 
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cancer.  This is likely because these women are following current medical 
recommendations to undergo screening annually since they are over the age of 40.   
When looking specifically at mammography screening, we found that women 
with a BRCA1 mutation who developed cancer at age 50 or older were more likely 
to have had a mammogram when compared to those who developed cancer prior to 
age 50.  Again, this is quite likely due to current breast cancer screening for the 
general population and younger women most likely received their first mammogram 
for diagnostic purposes.  We did not see this difference in BRCA2 mutation carriers.  
We cannot explain the difference between these two groups. 
In women with a BRCA1 or BRCA2 mutation who developed cancer at age 
50 or older, we found that they were more likely to have had a breast MRI than 
women who developed cancer prior to age 50.  This was an interesting result given 
that breast MRI is recommended to all women with a BRCA mutation.  It is possible 
that women who developed cancer at age 50 or older may have known about their 
BRCA mutation prior to developing cancer and began screening recommendations 
for that population whereas those who developed cancer prior to age 50 may have 
not had knowledge of their BRCA mutation prior to developing their own cancer and 
had not received screening recommendations for BRCA carriers.  Women who 
developed their cancer later in life are more likely to have had other family members 
diagnosed with cancer, given the older ages of their relatives, and therefore may 
have had knowledge of their BRCA mutation, or may have been receiving breast 
MRIs due to their family history, prior to their own cancer diagnosis. 
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We found that BRCA1 carriers with no cancer were less likely to have had a 
clinical breast exam when compared to those who developed cancer at age 50 or 
older.  Women undergoing more screening are more likely to have a breast cancer 
diagnosis because the cancer may be detected by screening.  This same 
difference, however, was not seen in BRCA2 mutation carriers; there was no 
difference when comparing those who developed cancer at age 50 or older to those 
with no cancer diagnosis.  We found no difference in the proportion of women who 
had received a clinical breast exam when comparing those diagnosed at age 50 or 
older to those who were diagnosed before age 50. 
We found no difference in the proportion of women undergoing ovarian 
cancer screening (CA-125 blood test or transvaginal ultrasound) when comparing 
those who developed cancer prior to age 50 and those who developed cancer at 
age 50 or older.  In addition, there was no difference in the proportion of women 
undergoing ovarian cancer screening when comparing those who developed cancer 
at age 50 or older and those who had never developed cancer. 
 
CHEMOPREVENTION USE 
We were unable to analyze data comparing the use of chemopreventive 
agents among the groups.  Chemoprevention use was not mentioned in the majority 
of the medical records for women who had a cancer diagnosis.  In women who had 
not had a cancer diagnosis we found that 56% of BRCA1 carriers and 88% of 
BRCA2 carriers had used tamoxifen.  The use of tamoxifen in BRCA1 mutation 
carriers may be less than BRCA2 carriers because it is known that BRCA1 positive 
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women are more likely to have a triple-negative (ER/PR/Her2/neu status) breast 
cancer and tamoxifen is not protective against triple-negative breast cancers.  
Women with a BRCA1 mutation may feel as though tamoxifen is not as effective 
against breast cancer as it is in the general population, so fewer women may 
choose to use it.  In addition, it has been previously reported that women are 
concerned about the side effects of tamoxifen, leading some women to decline its 
use as a chemopreventive agent (63). 
    
RISK-REDUCING SURGERIES 
Women with a BRCA1 or BRCA2 mutation who developed cancer prior to 
age 50 underwent prophylactic surgeries at a statistically significant younger age 
than those who developed cancer at age 50 or older.  Studies have found that the 
median time to risk-reducing surgery is approximately four months after learning 
about a positive BRCA result (64).  Women who developed cancer under age 50 
likely found out about their BRCA status earlier than those who developed cancer at 
age 50 or older and, therefore, underwent their risk-reducing surgery at an earlier 
age. 
We found that women over age 50 with no cancer diagnosis were more likely 
to have undergone a risk-reducing surgery than those who had developed cancer at 
age 50 or older.  This is expected because these women have not developed 
cancer and it is likely that this is due to their risk-reducing surgery.  Risk-reducing 
BSO reduces breast cancer risk by approximately 50% and ovarian cancer by up to 
96% (37, 38, 41-43).  However, the average age that women over age 50 with no 
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cancer diagnosis underwent their risk-reducing surgery was 51.78 in BRCA1 
mutation carriers and 53.78 in BRCA2 mutation carriers.  They did not undergo 
surgery at a younger age than women who developed cancer at age 50 or older. 
When comparing average age at diagnosis and average age of surgery, it is 
interesting to note that women who developed cancer prior to age 50 appear to 
have undergone risk-reducing surgery after their cancer diagnosis and women who 
developed cancer at age 50 or older seem to have undergone risk-reducing surgery 
prior to developing their first cancer.  This may be due to the risk-reducing surgery 
delaying the development of cancer in these individuals.  From this observation, it 
seems as though women diagnosed with cancer will undergo a risk-reducing 
surgery sooner than those with no cancer diagnosis, however this may also be due 
to these women finding out about their BRCA status at a younger age as well.  In 
our study, in each of the groups of women over the age of 50, they underwent their 
surgeries at a similar age.  It appears as though with no cancer diagnosis, women 
will wait until a later age to pursue risk-reducing surgery, however it does not seem 
as though a cancer diagnosis impacts their decision.  It is likely that the woman’s 
family history of cancer, knowledge of cancer risks, knowledge of BRCA status, and 
recommendations from physicians impact her decision to undergo risk-reducing 
procedures.   
There was no difference in the age at risk-reducing surgery among BRCA1 
or BRCA2 women who developed cancer at age 50 or older when compared to 
those who had never had a cancer diagnosis.  Again, it appears as though the 
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cancer diagnosis in the women diagnosed at a younger age probably impacts their 
decision to undergo risk-reducing surgery at a younger age.  
There were only three women over the age of 50 who had not developed 
cancer that had never undergone any risk-reducing surgeries.  These women were 
last seen at MD Anderson at ages 51, 53, and 82.  Because of the small number of 
women who have not undergone risk-reducing surgeries, it is difficult to draw 
conclusions about some of the findings when comparing women who developed 
cancer at age 50 or older to those who have never developed cancer.  The other 
women in this category may have developed cancer if it were not for their risk-
reducing surgeries.  While risk-reducing surgeries are not 100% preventive, it is 
known that bilateral mastectomy reduces the breast cancer risk by 90% (41) and 
BSO reduces breast cancer risk by 50% and ovarian cancer risk by up to 96% (37, 
38, 42, 43).  The majority of women who underwent risk-reducing surgery did not 
undergo bilateral mastectomy, so they do still have a risk to develop breast cancer.   
 
TUMOR CHARACTERISTICS  
We found that women with a BRCA2 mutation who developed cancer at age 
50 or older were more likely to have an ER/PR negative breast cancer than those 
who developed breast cancer prior to age 50.  While women with early-onset breast 
cancer are more likely to have ER/PR negative tumors than women with later-onset 
breast cancer, one study did find that BRCA2 mutation carriers whose cancer was 
diagnosed at a later age were more likely to have ER/PR negative tumors (47).  The 
reason for this finding is unknown at this time and more research about women with 
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BRCA2 mutations and ER/PR negative tumors is warranted as this may lead to 
clinical implications when discussing endocrine therapies for breast cancer. 
There was no difference in ER or PR status in women with a BRCA1 
mutation when comparing those who developed cancer prior to age 50 to those who 
developed cancer at age 50 or older.  This is likely because women with a BRCA1 
mutation are more likely to have a triple-negative breast cancer, therefore women 
with early or late onset breast cancer do not differ significantly in their ER/PR status.   
We did not find a difference in Her2/neu status when comparing women with 
a BRCA1 or BRCA2 diagnosed prior to age 50 to those diagnosed at age 50 or 
older.  In the study by Atchley et al, (47) they found that women with a BRCA2 
mutation with later-onset breast cancer were more likely to have Her-2/neu negative 
breast cancers.  In our study, there was no statistically significant difference in Her-
2/neu status in women diagnosed before age 50 and those diagnosed at age 50 or 
older. 
 
ETHNICITY 
We identified a difference in the ethnicity distribution in both BRCA1 and 
BRCA2 mutation carriers when comparing women who developed cancer prior to 
age 50 to those who developed cancer at age 50 or older.  From our data, it 
appears as though Ashkenazi Jewish women and women of “other” race develop 
cancer at an older age when compared to other ethnicities.  It also appears as 
though Hispanic women with a BRCA2 mutation develop cancer at a younger age 
when compared to other ethnicities.  The majority of the women included in our 
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study were Caucasian, therefore it would be beneficial to look at these populations 
in greater numbers to determine whether there is a significant difference in their 
cancer risks based on ethnicity.  To our knowledge, there have been no published 
reports about early vs. late cancer diagnosis in BRCA1 or BRCA2 mutation carriers 
among different ethnicities.   
 
FAMILY HISTORY 
We found that women over the age of 50 with no cancer diagnosis were 
more likely to have 2 or 3 first-degree relatives diagnosed with a breast or ovarian 
cancer while those diagnosed with cancer at age 50 or older were more likely to 
have 0 or 1 relative with a breast or ovarian cancer diagnosis.  Women with no 
breast cancer were more likely to have undergone a risk-reducing surgery than 
those who had developed breast cancer at age 50 or older and this may be due to 
having seen more relatives affected with a breast or ovarian cancer or having prior 
knowledge of a BRCA mutation in the family.  While the p-value approached 
significance (p=0.054), we did not identify any statistical significance between these 
groups when looking at the percentage of first-degree relatives diagnosed with a 
breast or ovarian cancer. 
All of the women with a BRCA1 mutation in our study who had not developed 
cancer had at least one first-degree relative who developed breast or ovarian 
cancer prior to age 50.  This was statistically different than the group of women who 
developed cancer at age 50 or older.  We found that 66% of women diagnosed with 
cancer at age 50 or older had a first-degree relative who was diagnosed with breast 
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or ovarian cancer before 50 years of age and 34% of them did not have a first-
degree relative diagnosed under age 50.  From this data, it appears as though 
women with no cancer have more early-onset breast and/or ovarian cancer in their 
first-degree relatives, however the majority of the women with no cancer had a risk-
reducing surgery.  It is likely that these women underwent their surgery due to many 
family members having a breast or ovarian cancer diagnosis or may be due to prior 
knowledge of a BRCA mutation in the family. 
Women who developed cancer prior to age 50 were not more likely to have a 
first-degree relative diagnosed under age 50 when compared to the group of 
women who developed cancer at age 50 or older.  From this information, it does not 
appear that early-onset breast cancer in a first-degree relative predicts early-onset 
breast cancer in another first-degree relative.  Likewise, it does not appear that 
having a first-degree relative with cancer diagnosed at age 50 or older predicts 
later-age of cancer onset in women with a BRCA1 mutation.  When comparing 
women with cancer at age 50 or older to those diagnosed before 50 or those who 
had not had a cancer diagnosis, there was no difference in whether or not they had 
a first-degree relative diagnosed with breast or ovarian cancer at age 50 or older. 
Women with a BRCA2 mutation who developed cancer before age 50 were 
more likely to have no breast or ovarian cancer diagnoses in their first-degree 
relatives when compared to women who developed cancer at age 50 or older.  
When we looked at the percentage of first-degree relatives with a cancer diagnosis, 
we found that women who developed cancer before age 50 were more likely to 
have 0% of their relatives affected with breast cancer while those who developed 
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cancer at age 50 or older were more likely to have 1-25% of their first-degree 
relatives affected.  These results may likely be due to the ages of first-degree 
relatives in the family because women under age 50 may have younger relatives 
than those who developed cancer at age 50 or later.  Women over age 50 are more 
likely to have more relatives that are of older ages when compared to the women 
who developed cancer under age 50. Because age is a risk factor for breast and 
ovarian cancer, it may be that the first-degree relatives of women who had cancer 
under age 50 have not yet developed cancer but may have a cancer diagnosis in 
the future.  This result is likely due to ascertainment bias. 
Women with a BRCA2 mutation who developed cancer at age 50 or older did 
not differ in the number or percentage of family members with breast or ovarian 
cancer when compared to women who had not developed cancer.  From this data, it 
does not appear that the number of family members with a cancer diagnosis affects 
the chance that a woman will develop cancer. 
There was no difference between women with a BRCA2 mutation who 
developed cancer at age 50 or older and those who developed cancer prior to age 
50 when investigating whether they had any first degree relatives with a breast or 
ovarian cancer diagnosis under age 50.  Similarly, we did not find any difference in 
whether or not a woman had a first-degree relative with breast or ovarian cancer 
under 50 when comparing women who developed cancer at age 50 or older to 
those who had never developed cancer.  It does not appear that having a first-
degree relative with a cancer diagnosis under age 50 increases the risk for early-
onset breast or ovarian cancer in women with a BRCA2 mutation. 
 70 
 
We found that women with a BRCA2 mutation who developed cancer at age 
50 or older were more likely to have a first-degree relative diagnosed with cancer at 
age 50 or older when compared to women who developed cancer prior to age 50.  
This trend may be present for two different reasons.  Women with a history of later-
onset breast cancer may develop later-onset breast cancer themselves or it may be 
that women who developed cancer before age 50 have fewer first-degree relatives 
over the age of 50 and, therefore, are less likely to have cancer diagnosed at age 
50 or older.  This finding may be due to ascertainment bias, therefore more studies 
on age at diagnosis in family members may be warranted. 
When combining first- and second-degree family members’ cancer histories, 
it does not appear that there is any significant difference between any of the groups.  
It does not appear that the number of first- and second-degree relatives with a 
cancer diagnosis has an impact on early vs. late cancer diagnosis in women with a 
BRCA1 or BRCA2 mutation.  From our study, it is not evident that the age of onset 
within a family with a BRCA1 or BRCA2 mutation can predict the age of onset for 
other individuals within the family. 
 
SUMMARY OF ASSOCIATIONS 
 Among our population of women with a BRCA1 or BRCA2 mutation we 
identified several significant and interesting observations.  We found that women 
who developed their first cancer at or after age 50 appear to have an approximately 
equal chance to develop ovarian cancer as they do to develop breast cancer.  We 
also found that reproductive risk factors and BMI do not appear to play a significant 
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role in the development of breast or ovarian cancer among these women, however 
further studies on the effect of age at menopause should be performed.  Women 
with a BRCA2 mutation who developed breast cancer at or after age 50 were more 
likely to have an ER/PR negative tumors than those who developed their breast 
cancer prior to age 50.  Ethnicity may play a role in the development of early vs. late 
onset of breast or ovarian cancer.  Women of Ashkenazi Jewish descent with a 
BRCA1 mutation appear to be more likely to develop late-onset breast or ovarian 
cancer, whereas Hispanic women with a BRCA2 mutation seem to be more likely to 
have an early-onset of breast or ovarian cancer.  Family history of breast and 
ovarian cancer may have an impact on the development of these cancers in an 
individual, however this is not clear in our study and additional investigation on this 
topic is warranted. 
 
STUDY LIMITATIONS  
There have been several limitations of the current study noted.  The main 
limitation to our study is ascertainment bias.  All of the women included in this study 
were patients at MD Anderson and, therefore, they likely either had a diagnosis of 
breast or ovarian cancer or had a relative with breast or ovarian cancer.  Therefore, 
our population is highly skewed toward women who have a family history of cancer 
or have had a breast or ovarian cancer diagnosis.  In addition, our study only 
included women who have knowledge of their BRCA mutation, so we were unable 
to evaluate factors among women who have a BRCA mutation but do not have 
knowledge of their BRCA status.  This information would have likely been very 
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helpful when studying reproductive risk factors, however would likely not play a 
significant role when exploring screening frequencies/modalities and risk-reduction 
surgeries. 
Because this was a retrospective study, we were unable to obtain all relevant 
information on every patient.  In identifying some factors, there was information 
missing on certain individuals.  It is possible that this information would lead us to 
find some significance in our analyses, however it is unlikely that this missing 
information would alter the analyses a significant amount. 
Another limitation to our study is that the family history information obtained 
was via patient report and was not validated using medical records.  It is possible 
that some cancer diagnoses were misreported or under-reported due to patients not 
recalling certain cancer diagnoses or recalling cancer diagnoses that did not truly 
exist. 
An additional limitation to this study is that we are unable to predict whether 
the women who have not yet developed cancer will develop cancer in the future.  
The average age of women with no cancer diagnosis in this study was 59.5 and 
56.88 in BRCA1 and BRCA2 mutation carriers, respectively.  These women may 
still develop cancer in their lifetime, however we cannot predict whether or not they 
will develop cancer, so this is a limitation in that we do not know which women will 
go on to develop cancer or when they will develop it.  Some women in this group 
may be more similar to women diagnosed with cancer at age 50 or older, however 
we are not able to ascertain which individuals may develop cancer. 
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Only those women who underwent risk-reducing bilateral mastectomy were 
recorded.  Women who underwent a unilateral prophylactic mastectomy following a 
breast cancer diagnosis in the contralateral breast were not recorded as having a 
prophylactic mastectomy.  Because we were interested in the age at the first breast 
or ovarian cancer diagnosis, we did not feel it was necessary as the prophylactic 
mastectomy was part of the treatment for the cancer in the contralateral breast.  
There were no cases where a unilateral mastectomy was performed without a 
breast cancer diagnosis. 
We did not analyze the date at which a woman underwent BRCA mutation 
analysis and at what age she learned of her BRCA1/2 mutation status.  This 
information would be beneficial in order to determine whether women underwent 
risk-reducing surgeries prior learning of their BRCA status or if they were more likely 
to undergo risk-reducing surgeries after a cancer diagnosis. 
 
IMPLICATIONS AND FUTURE RESEARCH 
 The further characterization of women with a BRCA1 or BRCA2 mutation 
who do not develop early-onset breast or ovarian cancer may aid in determining 
what factors are important in early vs. late-onset breast or ovarian cancer 
development.  A larger cohort of BRCA1 and BRCA2 mutation carriers with no 
cancer diagnosis prior to age 50 would be beneficial to determine whether or not the 
results are consistent with those in this study.  Additional research may also include 
investigating when a woman received knowledge of her BRCA1 or BRCA2 mutation 
and investigating whether this knowledge delays or prevents a cancer diagnosis, 
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perhaps through a prospective study.  Because there have not been any reports on 
BRCA1 or BRCA2 carriers with later-onset breast or ovarian cancer, confirmation of 
the results from this study as well as additional analyses in another population 
would be valuable.  In addition to further exploring the factors included in this study, 
research on the effect of possible modifier genes and their role in early or late 
development of breast and ovarian cancer may also be advantageous. 
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